Data from multiple sources - Curated by Marshall Pearce - Last updated 06 June 2017
Added 18 days ago Drug news
FDA accepts filing of Adcetris + chemo to treat advanced classical Hodgkin lymphoma.- Seattle Genetics.
Seattle Genetics, Inc. announced that the FDA has accepted for filing a supplemental Biologics License Application (BLA) for Adcetris (brentuximab...
Added 1 month ago Drug news
Phase III ECHELON-1 data presented at ASH for Adcetris + chemo to treat untreated advanced classical Hodgkin lymphoma.
Added 2 months ago Drug news
Innovative study presented at the American College of Rheumatology compare biosimilars with their reference medicines
Sandoz announces data from four clinical studies comparing proposed biosimilar adalimumab & biosimilar rituximab with their reference medicines, Humira and MabThera/Rituxan.
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The objective of this guideline is to provide healthcare professionals with guidance on the investigation and management of patients with...
Added 2 years ago
Guidelines on the management and admission to intensive care of critically ill adult patients with haematological malignancy in the UK
This guideline is intended to be of use to haematologists and intensivists practising in the UK, and outlines some of...
Added 2 years ago
The 2014 update elaborates on two histologically distinguished entities: classical Hodgkin's lymphoma that accounts about 95% of cases and nodular lymphocyte-predominant Hodgkin's lymphoma...
Added 1 year ago
Background: Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.
Added 1 month ago
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study.
Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning.
Added 4 months ago
Despite the success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma, there remains considerable uncertainty about their mechanism(s) of action.
Added 7 months ago
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD...
Added 2 months ago
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as...
Added 9 years ago
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
The primary objective for the phase I part of the study is to investigate the safety and tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy...
Added 9 months ago
Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more
Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.